BioInvent completes enrollment in BI-204 phase IIa study for atherosclerosis

BioInvent International AB (OMXS: BINV) and its collaborator Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that all patients have completed enrollment in the GLACIER study, a phase IIa study with BI-204 in patients with stable atherosclerotic vascular disease. BioInvent expects to publicly release top-line data from the study in Q3 2012.

Svein Mathisen, President and CEO of BioInvent, said: "We and our partner, Genentech, are eagerly awaiting the results from the GLACIER study. By applying the latest innovation in imaging technology we hope to show that BI-204 is bringing the treatment of atherosclerosis and acute coronary syndromes one step forward, addressing the disease at its root, atherosclerotic plaque inflammation".

Source: BioInvent International